Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Henderson reported for 6 months of 2024 by IFRS

8/27/24 HNFG

Cian Technology plans to offer minority shareholders a swap by the end of the year

8/27/24 CIAN

Board of Directors of Udmurtneft recommended dividends

8/27/24 UDMN

Board of Directors of Alrosa recommended dividends

8/27/24 ALRS

NKHP reported for 6 months of 2024 by IFRS

8/27/24 NKHP

Rosseti South reported for 6 months of 2024 by IFRS

8/27/24 MRKY

Magnit.Market increased the network of PVZ up to 2000 points

8/27/24 MGNT

Rosseti Kuban reported for 6 months of 2024 by IFRS

8/27/24 KUBE

Rosseti Volga reported for 6 months of 2024 by IFRS

8/27/24 MRKV

Polyus increased gold production by 3%

8/27/24 PLZL